Clinical Trial Update: Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update comparing evolocumab added to standard lipid-lowering therapy versus placebo on fasting and post-fat-load lipids in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Dysbetalipoproteinemia
• Hyperlipoproteinemia Type Iii

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: UMC Utrecht | Conditions: Familial Dysbetalipoproteinemia, Hyperlipoproteinemia Type III | Phase 4 | Status: UNKNOWN